Novo Nordisk | pharmaphorum

Saturday 23 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

Novo Nordisk

News

Lilly trumpets new weight-loss data with Mounjaro

Lilly trumpets new weight-loss data with Mounjaro

Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.

News

Lilly goes toe-to-toe with Novo Nordisk on obesity

Lilly goes toe-to-toe with Novo Nordisk on obesity

Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera

News

Aspect Biosystems

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

News

CHMP backs obesity drug Wegovy for teens

CHMP backs obesity drug Wegovy for teens

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

Market Access

chess pieces

Capping the cost of insulin: altruistic or strategic?

The price of insulin has become one of the most talked about issues across the pharma industry.

News

Novo Nordisk suspended from ABPI after code breach

Novo Nordisk suspended from ABPI after code breach

The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.